Lynx1 Capital Management
Latest statistics and disclosures from Lynx1 Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRUS, STOK, GHRS, CCCC, TCRX, and represent 90.21% of Lynx1 Capital Management's stock portfolio.
- Added to shares of these 10 stocks: STOK (+$20M), CCCC (+$15M), GHRS (+$7.7M), CGEM (+$6.6M), ALLO (+$5.2M), LBPH, PIRS, KNSA, PASG, KRRO.
- Started 7 new stock positions in ALLO, CGEM, VYNE, KNSA, PIRS, LBPH, KRRO.
- Reduced shares in these 10 stocks: Alpine Immune Sciences (-$89M), MRUS (-$18M), CABA (-$12M), SLN (-$11M), AUTL (-$8.9M), Kinnate Biopharma (-$5.3M), NKTR, Pieris Pharmaceuticals, IBIO, BNOX.
- Sold out of its positions in Alpine Immune Sciences, AUTL, Kinnate Biopharma, NKTR, Pieris Pharmaceuticals, SLN.
- Lynx1 Capital Management was a net seller of stock by $-89M.
- Lynx1 Capital Management has $277M in assets under management (AUM), dropping by -28.60%.
- Central Index Key (CIK): 0001910456
Tip: Access up to 7 years of quarterly data
Positions held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 18 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Merus N V (MRUS) | 25.8 | $71M | -20% | 1.2M | 59.17 |
|
| Stoke Therapeutics (STOK) | 25.3 | $70M | +40% | 5.2M | 13.51 |
|
| Gh Research Ordinary Shares (GHRS) | 16.7 | $46M | +19% | 4.0M | 11.66 |
|
| C4 Therapeutics Com Stk (CCCC) | 11.5 | $32M | +89% | 6.9M | 4.62 |
|
| Tscan Therapeutics (TCRX) | 11.0 | $31M | 5.2M | 5.85 |
|
|
| Cullinan Oncology (CGEM) | 2.4 | $6.6M | NEW | 377k | 17.44 |
|
| Allogene Therapeutics (ALLO) | 1.9 | $5.2M | NEW | 2.2M | 2.33 |
|
| Longboard Pharmaceuticals In (LBPH) | 1.6 | $4.5M | NEW | 167k | 27.03 |
|
| Passage Bio (PASG) | 1.4 | $4.0M | +4% | 5.1M | 0.79 |
|
| Cabaletta Bio (CABA) | 1.3 | $3.7M | -76% | 492k | 7.48 |
|
| Ibio Con New (IBIO) | 0.5 | $1.3M | -59% | 600k | 2.11 |
|
| Ibio Con New (IBIO) | 0.2 | $508k | -59% | 241k | 2.11 |
|
| Bionomics Ads (BNOX) | 0.2 | $460k | -26% | 600k | 0.77 |
|
| Pieris Pharmaceuticals Com New (PIRS) | 0.2 | $427k | NEW | 44k | 9.81 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.1 | $177k | NEW | 9.5k | 18.67 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.1 | $157k | 17k | 9.03 |
|
|
| Korro Bio (KRRO) | 0.0 | $129k | NEW | 3.8k | 33.87 |
|
| Vyne Therapeutics (VYNE) | 0.0 | $32k | NEW | 16k | 1.97 |
|
Past Filings by Lynx1 Capital Management
SEC 13F filings are viewable for Lynx1 Capital Management going back to 2021
- Lynx1 Capital Management 2024 Q2 amended filed Aug. 19, 2024
- Lynx1 Capital Management 2024 Q2 filed Aug. 14, 2024
- Lynx1 Capital Management 2024 Q1 amended filed May 30, 2024
- Lynx1 Capital Management 2024 Q1 filed May 15, 2024
- Lynx1 Capital Management 2023 Q4 filed Feb. 14, 2024
- Lynx1 Capital Management 2023 Q3 filed Nov. 14, 2023
- Lynx1 Capital Management 2023 Q2 filed Aug. 14, 2023
- Lynx1 Capital Management 2023 Q1 filed May 15, 2023
- Lynx1 Capital Management 2022 Q4 filed Feb. 14, 2023
- Lynx1 Capital Management 2022 Q3 filed Nov. 14, 2022
- Lynx1 Capital Management 2022 Q2 filed Aug. 15, 2022
- Lynx1 Capital Management 2022 Q1 filed May 16, 2022
- Lynx1 Capital Management 2021 Q4 filed Feb. 14, 2022